Host genetics of tuberculosis susceptibility

Erwin Schurr

McGill International TB Centre

Departments of Medicine and Human Genetics

McGill University, Montreal, Quebec, Canada

But what exactly is a genetic disease?

Phenylketonuria (PKU) is a metabolic disease that is caused by phenylalanine:


No phenylalanine = No PKU!

Is PKU a genetic disease? YES!

Phenylalanine is an environmental factors that is NECESSARY but NOT SUFFICIENT for disease (PKU) expression

M. tuberculosis is necessary, but is it sufficient?

Tuberculosis Pathogenesis



M. tuberculosis is not sufficient to cause TB

Three examples that support a role of genetic predisposition to clinical tuberculosis disease:

- (i) the Lübeck accident
- (ii) risk of tuberculosis recurrence
- (iii) twin studies

The Lübeck Accident

Virulence level		Disease severity						
	Number	death	serious disease	mild symptoms	no symptoms			
1	1	-	-	-	1			
2	93	6 = 6.5%	9 = 9.7%	78 = 83.8%	-			
3	83	18 = 21.7%	34 = 41.0%	31 = 37.3%	-			
4	74	53 = 71,6%	18 = 24.3%	3 = 4.1%	-			
Totals	251	77	61	112	1			

Risk of Recurrence of TB



TABLE 3. PROPORTION AND RATE OF RECURRENCES AND REINFECTION DISEASE IN ENROLLED PATIENTS BY OUTCOME OF FIRST DISEASE EPISODE

Outcome of First Episode with DNA FP	No. Patients	PYRS Follow-up	No. Recurrences	Recurrence Rate/ 100 PYRS	No. DNA FP in Second Episode	No. Confirmed Reinfections (%)	Confirmed Reinfection Disease Rate/100 PYRS (95% CI)	Likely Reinfection Disease Rate/100 PYRS† (95% CI)
Cure*	358	1,794	48	2.7	21	19 (90)	1.1 (0.7-1.7)	2.4 (1.4-3.8)
TC*	89	466	13	2.8	10	5 (50)	1.1 (0.3-2.5)	1.4 (0.5-3.3)
Default	165	725	47	6.5	37	4 (11)	0.6 (0.2–1.4)	0.7 (0.2-1.6)

Definition of abbreviations: CI = confidence interval; FP = fingerprint; PYRS = person-years; TC = treatment completed.


Re-infection disease rate of 2.2/100 PYRS corresponds to 4 times the age-adjusted incidence

^{*} For successful treatment (either cure or TC) confirmed reinfections are 24 of 31 (77%), confirmed reinfection disease rate is 1.1 (0.7–1.6) per 100 PYRS, and likely reinfection disease rate is 2.2 (1.6–2.9) per 100 PYRS.

[†] The likely reinfection disease rate is the recurrence rate multiplied with the proportion confirmed reinfections among recurrences with a DNA FP available.

Twin studies

DZ TWINS




2 fertilizations



Share 50% of genetic background


MZ TWINS



1 fertilization

Share 100% of genetic background

Twin studies




Significant excess of concordance among monozygous twins demonstrates the importance of host genetic factors

Candidate gene approaches

Many examples - one selected gene: NRAMP1

Candidate *NRAMP1*: TB outbreak



- Entire pedigree: 85 individuals
- Genotypes available from 65 individuals
- Majority of cases occurred within 6 months of diagnosis of index case
- Last case was diagnosed 2 years after index case
- Case criteria: clinical sign of active disease PLUS culture OR response to anti-TB therapy

Candidate *NRAMP1*: TB outbreak

Penet	# individuals			
Low risk al	llele	High risk allele		
RR=10	RR=100		<u></u>	
0.085	0.0085	0.85	42	
0.037	0.0037	0.37	11	
0.010	0.0010	0.10	7	
0.425	0.2125	0.85	7	
			14	
	RR=10 0.085 0.037	Low risk allele RR=10 RR=100 0.085 0.0085 0.037 0.0037 0.010 0.0010	RR=10 RR=100 0.085 0.0085 0.85 0.037 0.0037 0.37 0.010 0.0010 0.10	

Candidate *NRAMP1*: TB outbreak


With liability classes: Strong evidence for strong genetic effect (NRAMP1)

P = < 0.000001, RR=10

Without liability classes: NO evidence for any genetic effect

Greenwood et al. Am J Hum Genet 67:405, 2000

Environmental setting defines the playing field for genetic factor



Baghdadi et al. J Exp Med. 2006 Jul 10;203(7):1679-84.


Table 1. Genetic Association Results for Replicated SNPs rs 1568952 and rs 2726600 in the Primary Moro ccan Family-Based Study, the Moroccan Case-Control Replication Study, and Combined Analyses under the Recessive Model for the Minor Allele

Stratum	SNP	Minor Allele	Major Allele	MAP	Family-Based Study		Case-Control Study		Combined	
					OR (95% CI)	p Value ^b	OR (95% CI)	p Value ^b	OR (95% CI)	p Value ^b
Full	rs1568952	A	G	0.36	3.21 (1.41-7.35)	0.007	1.98 (1.33-2.94)	6 × 10 ⁻⁴	2.18 (1.53-3.10)	1.1×10^{-5}
	rs2726600	G	A	0.40	2.65 (1.27-5.56)	0.0093	1.61 (1.12-2.31)	0.0092	1.81 (1.34-2.43)	9.2 × 10 ⁻⁵
<25 Years	rs1568952	A	G	-	5.54 (1.97-15.53)	0.0003	2.86 (1.72-4.77)	2.9×10^{-5}	3.09 (1.99-4.78)	4.4×10^{-6}
	rs2726600	G	A	-	2.56 (1.37-4.80)	0.0025	2.00 (1.24-3.23)	0.0039	2.19 (1.52-3.14)	3.2×10^{-5}
≥25 Years	rs1568952	A	G	-	0.65 (0.12-3.66)	0.62	1.52 (0.93-2.47)	0.094	1.42 (0.88-2.27)	0.15
	rs2726600	G	Α	-	1.73 (0.56-5.33)	0.33	1.38 (0.89-2.14)	0.15	1.42 (0.95-2.13)	0.09

The following abbreviations are used: MAF, minor allele frequency; OR, odds ratio; and CI, confidence interval.


^{*}MAF was estimated from among 316 founders.

^bAll p values are two sided.



Genome-wide association studies (GWAS)

GWAS TB




Thye et al. Nat Genet. 2010 Sep;42(9):739-41

Thye et al. Nat Genet. 2012 Feb 5;44(3):257-9

Chromosome 18 locus not replicated outside of West Africa

Chromosome 11 locus replicated outside of West Africa

Tuberculosis Pathogenesis



Latent M. tuberculosis infection

How do we measure infection?

No "gold standard"

Three types of assays

In vivo tuberculin skin test (TST)

In vitro production of antigen-specific IFNy production (ELISA)

In vitro determination of frequency/number of antigen-specific T-cells
(ELISpot/FACS)

Tuberculin Skin Test





Detection of people infected by M. tuberculosis



Intrinsically a quantitative measure

Max Lurie's Rabbits





Cavitary disease

Mean survival 9.2 months

S S

Disseminated disease

Mean survival 4.8 months


Innate resistance



20-40% no disease 85% Tuberculin test negative 11-19 months of exposure

Werneck-Barroso E. Int J Tuberc Lung Dis 1999;3:166-68

Lurie's rabbits



Werneck-Barroso E. Int J Tuberc Lung Dis 1999;3:166-68

Genetics of LTBI: TST

✓ **Familial correlation studies**: heritability between 30 à 90%

(Sepulveda et al., Am J Respir Crit Care Med, 1994 / Tuber Lung Dis, 1994) (Jepson et al., Infect Immun, 2001)

✓ Molecular studies :

• linkage study in Uganda (Stein et al., Plos One, 2008)

• Candidate gene *IL10* and binary Mantoux

(Thye et al., Plos One, 2009; Zembrzuski et al., Tuberculosis, 2010)

•*Il12RB1* and *TLR2* polymorphisms and persistent TST-negativity

Stein et al Poster X7 4020, Keystone Meeting, Host Response in Tuberculosis Whistler, March 13-18, 2013

Extent of TST reactivity

Familial correlation compatible with a major gene effect?


⇒ Complex Segregation Analysis (CSA)

A major gene controls TST reactivity in Colombia


Codominant gene (p<10⁻⁶), MAF: 0.41 (predisposing to high reactivity)

35% (17%) predisposed to low (high) values

⇒ explains 72% of TST residual variability!




A "what does it mean" example




Mean TST

Genetic linkage study of TST reactivity


Location: Cape Town, South Africa




TST distribution is bimodal




Major locus for TST negativity per se (TST1) maps to 11p14



Household contact study in Paris






ENDOPHENOTYPES


134 nuclear families [2-6 sibs]; 390 children; whole blood assays


TNF production by whole blood after stimulation by:



Bivariate linkage analysis of TNF production 6 5 LOD score Information content 1 0 2 **Chromosomes Chromosome 11** 5 LOD score Information content 3 2 Cobat et al Clin Infect Dis. 2013 Oct;57(7):963-70 Mb 10 20 30

Major pleiotropic locus for BCG-triggered TNF overlaps innate resistance to *Mtb* infection locus!





Take-home message I

- Host genetic background is a major confounder of TST reactivity
- **A** major locus on chromosome 11p controls TST = 0

How to interpret TST = 0?

- A false positive
- Anergy
- Lack of exposure
- Resistance to LTBI

Take-home message II

Genetics suggests a connection between innate resistance to *Mtb* infection with innate efficiency to produce TNF









McGill Center for the Study of Host Resistance

C. Gallant, M. Orlova, L. Simkin, A. Cobat


McGill University, Montréal

Human Genetics of Infectious Diseases

JL. Casanova, S. Dupuis

L. Abel, A. Alcaïs, A Cobat

Necker Branch, Paris



E. Hoal, G. Black, P. van Helden Stellenbosch University, Cape Town J. Hughes, B.Eley, W.Hanekom University of Cape Town, Cape Town